TheraRadar
← Back
Data updated: Sep 20, 2026

MSN

Generics
OncologyCardiovascularNeurology

MSN is a generic drug manufacturer focused on Oncology, Cardiovascular, Neurology. Key products include OLUMIANT.

2017
Since
106
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
1 Small Molecules

FDA Novel Drug Designations

(2018)
1 Novel
See 1 novel approval →
2018 OLUMIANT (BARICITINIB)

MSN's Recent FDA Approvals

MSN secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
PYRIDOSTIGMINE BROMIDE NDA
2024-10-04
pyridostigmine bromide
INDICATIONS AND USAGE Pyridostigmine Bromide Tablets USP are useful in the treatment of myasthenia gravis.

MSN's Therapeutic Areas

MSN's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 33%
13 drugs
Cardiovascular 28%
11 drugs
Neurology 20%
8 drugs
Respiratory 10%
4 drugs
Gastroenterology 10%
4 drugs

MSN's Top Competitors

MSN's closest competitors by therapeutic-area and drug-target overlap include Novartis, GE HEALTHCARE, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma
Oncology, Cardiovascular, Respiratory
GE HEALTHCARE specialty
Neurology, Cardiovascular, Oncology, Respiratory
Merck big-pharma
Oncology, Cardiovascular, Respiratory
AZURITY specialty
Cardiovascular, Oncology, Neurology, Respiratory
Bayer big-pharma
Oncology, Cardiovascular, Respiratory

MSN Pipeline Snapshot

Active clinical trials for MSN across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • OLUMIANT leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling